<DOC>
	<DOC>NCT01156363</DOC>
	<brief_summary>This open label, single arm study will assess the efficacy for long-term maintenance of haemoglobin levels and the safety and tolerability of methoxy polyethylene glycol-epoetin beta [Mircera] in dialysis patients with chronic renal anaemia. Patients on regular long-term haemodialysis or peritoneal dialysis will receive monthly subcutaneous or intravenous Mircera for 6 months. Target sample size is &lt;200 patients.</brief_summary>
	<brief_title>A Study of Monthly Subcutaneous or Intravenous Mircera in Dialysis Patients With Chronic Renal Anaemia</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<criteria>adult patients, &gt;/=18 years of age chronic renal anaemia haemoglobin 10.012.0g/dl at screening adequate iron status continuous stable ESA (erythropoietic stimulating agent) therapy for &gt;/= 2 months regular haemodialysis or regular peritoneal dialysis for &gt;/= 3 months uncontrolled hypertension haemoglobinopathy anaemia due to haemolysis pure red cell aplasia (PRCA)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>